Retrophin names CEO

Retrophin names CEO

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Global M&A by the Numbers: Q2 2022

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Infographic 2022 Top Tech Trends Shaping Corporations

Retrophin Inc. appointed Eric Dube president and CEO, effective Jan. 4.

Prior to joining Retrophin, Dube was president of North America at ViiV Healthcare, a GlaxoSmithKline PLC unit.

Dube succeeds Stephen Aselage, who is retiring. Aselage, who has been CEO since 2014, will continue to serve on Retrophin's board.

Dube will also serve on the board of the San Diego-based biopharmaceutical company, which develops therapies for rare diseases.